Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Mylan Rebate Suit

A federal court in New York granted class certification in a stockholder suit against pharmaceutical company Mylan accusing it of misclassifying its EpiPen as a generic drug and underpaying federal Medicaid rebates.

MANHATTAN – A federal court in New York granted class certification in a stockholder suit against pharmaceutical company Mylan accusing it of misclassifying its EpiPen as a generic drug and underpaying federal Medicaid rebates.

Categories / Business, Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...